These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1976270)

  • 41. [Comparison of the effects between standard doses of H2-blocker (famotidine 20mg b.d.) and proton pump inhibitor (omeprazole 20mg o.d.) in the treatment of refractory reflux esophagitis by ambulatory 24-hr intra-gastroesophageal pH monitoring].
    Yamashita Y; Kinoshita Y; Chihara K; Chiba T
    Nihon Shokakibyo Gakkai Zasshi; 1994 Dec; 91(12):2166-73. PubMed ID: 7837683
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Does a relationship still exist between gastroesophageal reflux and Helicobacter pylori in patients with reflux symptoms?
    Grande M; Lisi G; De Sanctis F; Grande S; Esser A; Campanelli M; Balassone V; Milito G; Villa M
    World J Surg Oncol; 2014 Dec; 12():375. PubMed ID: 25479911
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of famotidine 20 mg twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative reflux esophagitis.
    Wesdorp IC; Dekker W; Festen HP
    Dig Dis Sci; 1993 Dec; 38(12):2287-93. PubMed ID: 8261835
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Comparison between histamine H2-blocker and proton pump inhibitor on the effects of initial treatment in reflux esophagitis].
    Harasawa S
    Nihon Rinsho; 2000 Sep; 58(9):1847-52. PubMed ID: 11004814
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [A randomized, prospective, comparative, multicenter study of rabeprazole and ranitidine in the treatment of reflux esophagitis].
    Jeong HY; Lee BS; Sung JK; Lee TY; Yoon SJ; Kim SJ; Chung IK; Lee SH; Shin JE; Lee DS; Baek JT; Nam SW; Yoon SJ; Kim SH; Lee GS; Lee JM; Kim AN; Oh JI
    Korean J Gastroenterol; 2006 Jan; 47(1):15-21. PubMed ID: 16434864
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Long-term maintenance treatment of reflux esophagitis resistant to H2-RA with PPI (lansoprazole)].
    Endo M; Sugihara K
    Nihon Rinsho; 2000 Sep; 58(9):1865-70. PubMed ID: 11004817
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Esophageal aperistalsis and gastroesophageal reflux disorder: return of peristalsis after H2-blocker therapy.
    Meshkinpour H
    Am J Gastroenterol; 1995 Jun; 90(6):910-4. PubMed ID: 7771419
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of H2 receptor antagonists in the treatment of gastroesophageal reflux disease and its symptoms.
    Tougas G; Armstrong D
    Can J Gastroenterol; 1997 Sep; 11 Suppl B():51B-54B. PubMed ID: 9347179
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A double-blind, controlled study comparing lafutidine with placebo and famotidine in Japanese patients with mild reflux esophagitis.
    Ohara S; Haruma K; Kinoshita Y; Kusano M
    J Gastroenterol; 2010 Dec; 45(12):1219-27. PubMed ID: 20632193
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [H2-blockers in reflux-esophagitis].
    Berstad A
    Tidsskr Nor Laegeforen; 1983 Jul; 103(19-21):1439-41. PubMed ID: 6138879
    [No Abstract]   [Full Text] [Related]  

  • 51. Famotidine in the management of acid-reflux oesophagitis: a multicentre study.
    Bovero E; Poletti M; Iaquinto G; Giardulo N; Zambelli A; Pisano G; Cheli R
    Hepatogastroenterology; 1990 Dec; 37 Suppl 2():145-8. PubMed ID: 2083926
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Cost-effectiveness of the treatment of reflux esophagitis: proton pump inhibitor versus histamine-2-receptor antagonist].
    Habu Y; Oyasu K; Wakamatsu T; Sumitomo Y; Kiyota K; Inokuchi H; Kawai K
    Nihon Rinsho; 2000 Sep; 58(9):1881-5. PubMed ID: 11004820
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of childhood peptic esophagitis: a double-blind placebo-controlled trial of nizatidine.
    Simeone D; Caria MC; Miele E; Staiano A
    J Pediatr Gastroenterol Nutr; 1997 Jul; 25(1):51-5. PubMed ID: 9226527
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
    Hatlebakk JG; Berstad A
    Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevention of relapse in reflux esophagitis: a placebo controlled study of ranitidine 150 mg bid and 300 mg bid.
    Hegarty JH; Halvorsen L; Hazenberg BP; Nowak A; Smith CL; Thomson AB; Vantrappen G; McKenna CJ; Mills JG
    Can J Gastroenterol; 1997; 11(1):83-8. PubMed ID: 9113805
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Omeprazole in H2 receptor antagonist-resistant reflux esophagitis.
    Marciano-D'Amore DA; Paterson WG; Da Costa LR; Beck IT
    J Clin Gastroenterol; 1990 Dec; 12(6):616-20. PubMed ID: 1979984
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Management of symptoms in step-down therapy of gastroesophageal reflux disease.
    Mine S; Iida T; Tabata T; Kishikawa H; Tanaka Y
    J Gastroenterol Hepatol; 2005 Sep; 20(9):1365-70. PubMed ID: 16105122
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Usefulness of ranitidine in the treatment of esophagitis caused by gastro-esophageal acid reflux].
    Nervi M; Conte M; Buttitta F; Spisni R
    Minerva Dietol Gastroenterol; 1989; 35(3):195-9. PubMed ID: 2689913
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Famotidine 40mg B.I.D. in the treatment of reflux oesophagitis.
    Ahmed W; Qureshi H; Alam SE; Zuberi SJ
    J Pak Med Assoc; 1995 Sep; 45(9):241-3. PubMed ID: 8683830
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of three methods of intraesophageal pH recordings in the diagnosis of gastroesophageal reflux.
    Bianchi Porro G; Pace F
    Scand J Gastroenterol; 1988 Aug; 23(6):743-50. PubMed ID: 3175534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.